Neuroscience

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)…

2 years ago

Aurora Spine to Attend the American Association of Neurological Surgeons Annual Meeting

Carlsbad, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a…

2 years ago

Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy

BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMSMALVERN, Pa., April 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics,…

2 years ago

Cerevance Announces Poster Presentation at the BNA International Festival of Neuroscience

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous…

2 years ago

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology…

2 years ago

RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a…

2 years ago

AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed…

2 years ago